INOVIO PHARMACEUTICALS, INC. Income Statement
INO|15 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 15 fiscal years. All figures from audited SEC 10-K filings.
INOVIO PHARMACEUTICALS, INC. reported $217,756 in revenue and $107M in net loss for FY2025. Revenue has declined at a 23.4% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $217.8K | $832.0K | $1.8M | $7.4M | $4.1M | $30.5M | $42.2M | $35.4M | $40.6M | $10.5M | $13.5M | $4.1M | $9.8M | $6.1M | $9.1M |
| SG&A Expense | $37.0M | $47.6M | $53.8M | $37.2M | $27.2M | $29.3M | $28.3M | $23.9M | $18.1M | $15.9M | $13.6M | $10.8M | $12.0M | $12.1M | $13.7M |
| R&D Expense | $75.6M | $86.7M | $249.2M | $94.2M | $88.0M | $95.3M | $98.6M | $88.7M | $57.8M | $34.1M | $21.4M | $18.0M | $20.0M | $13.3M | $9.4M |
| Operating Income | -$112.4M | -$143.9M | -$301.2M | -$124.1M | -$111.1M | -$94.1M | -$83.6M | -$76.2M | -$34.3M | -$39.5M | -$19.5M | -$23.5M | -$21.6M | -$19.2M | -$14.0M |
| Interest Expense | - | - | $1.9M | $8.7M | $7.9M | $0 | $25.9K | - | - | - | - | - | - | - | - |
| Income Tax | $0 | $0 | $0 | $0 | -$257.3K | $2.2M | $0 | $0 | -$2.1M | $0 | $0 | $30.0K | $27.0K | $71.0K | - |
| Net Income | -$107.3M | -$135.1M | -$303.7M | -$166.4M | -$119.4M | -$97.0M | -$88.2M | -$73.7M | -$29.2M | -$36.1M | -$66.0M | -$19.7M | -$15.3M | -$17.6M | -$24.4M |
| EPS (Basic) | -$3.95 | -$6.09 | -$17.45 | -$1.07 | -$1.21 | -$0.83 | -$1.08 | -$1.01 | -$0.43 | -$0.61 | -$1.43 | -$0.58 | - | - | - |
| EPS (Diluted) | -$3.95 | -$6.09 | -$17.45 | -$1.07 | -$1.21 | -$0.83 | -$1.09 | -$1.01 | -$0.44 | -$0.64 | -$1.43 | -$0.58 | -$0.12 | -$0.17 | -$0.33 |
| Shares Outstanding | 36.1M | 22.8M | 21.1M | 217.4M | 186.9M | 101.4M | 97.2M | 90.4M | 74.1M | 72.2M | 60.7M | 52.6M | 144.3M | 135.0M | 105.0M |
| Operating Margin | -51616.9% | -17300.3% | -16972.3% | -1674.3% | -2702.1% | -308.7% | -198.1% | -215.6% | -84.5% | -377.7% | -145.1% | -570.4% | -220.9% | -312.8% | -153.0% |
| Profit Margin | -49254.3% | -16239.9% | -17109.9% | -2245.4% | -2902.8% | -318.1% | -208.9% | -208.5% | -71.9% | -345.4% | -490.3% | -477.6% | -155.7% | -286.6% | -267.7% |